DOW JONES, A NEWS CORP COMPANY
News Corp is a network of leading companies in the worlds of diversified media, news, education, and information services.
DOW JONES
NEWS CORP
ダウ平均 ▲
17531.07 0.17%
  S&P 500 ▲
2053.24 0.04%
  ナスダック ▲
4788.00 0.39%
  米10年債 ▲
0/32 yield 1.841%
  原油 ▲
48.16 -0.52%
  ユーロ／ドル ▲
1.1205 -0.19%
 
2016年5月23日
Sections
Subscribe Sign In

Cellectar Biosciences Inc. CLRB (U.S.: Nasdaq)

  • 10:25 AM EDT 05/23/16
  • $4.60 USD
  • 1.15 33.33%
  • Volume 13,354,776
  • DELAYED 15 MINUTES
  • Volume 13,354,776
  • 65 Day Avg Vol 732,693
  • 1 Day Range 3.03 - 4.84
  • 52 Week Range 1.00 - 38.89 (05/19/16 - 07/20/15)
Advanced Charting Compare
  • Compare to Benchmark:
  • DJIA
  • S&P 500
  • GLOBAL DOW
  • NASDAQ
  • Health Care/Life Sciences
  • Compare to
  • Open 3.43
  • Prior Close 3.45 (05/20/16)
  • 1 Day
  • CLRB 33.33%
  • DJIA 0.17%
  • Russell 2K 0.42%
  • Health Care/Life Sciences 1.05%
Key Stock Data
?
P/E Ratio (TTM)
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for the trailing 12 month period.
Earnings Per Share (TTM)
A company's net income for the trailing twelve month period expressed as a dollar amount per fully diluted shares outstanding.
Market Capitalization
Reflects the total market value of a company. Market Cap is calculated by multiplying the number of shares outstanding by the stock's price. For companies with multiple common share classes, market capitalization includes both classes.
Shares Outstanding
Number of shares that are currently held by investors, including restricted shares owned by the company's officers and insiders as well as those held by the public.
Public Float
The number of shares in the hands of public investors and available to trade. To calculate, start with total shares outstanding and subtract the number of restricted shares. Restricted stock typically is that issued to company insiders with limits on when it may be traded.
Dividend Yield
A company's dividend expressed as a percentage of its current stock price.

Key Stock Data

  • P/E Ratio (TTM)
    N/A
  • EPS (TTM)
    N/A
  • Market Cap
    N/A
  • Shares Outstanding
    3.83 M
  • Public Float
    589,023
  • Yield
    CLRB has not issued dividends in more than 1 year.
  • Latest Dividend
    N/A
  • Ex-Dividend Date
    N/A
?
Shares Sold Short
The total number of shares of a security that have been sold short and not yet repurchased.
Change from Last
Percentage change in short interest from the previous report to the most recent report. Exchanges report short interest twice a month.
Percent of Float
Total short positions relative to the number of shares available to trade.

Short Interest (04/29/16)

  • Shares Sold Short
    24,311
  • Change from Last
    -64.79%
  • Percent of Float
    4.13%
?
Money Flow Uptick/Downtick Ratio
Money flow measures the relative buying and selling pressure on a stock, based on the value of trades made on an "uptick" in price and the value of trades made on a "downtick" in price. The up/down ratio is calculated by dividing the value of uptick trades by the value of downtick trades. Net money flow is the value of uptick trades minus the value of downtick trades. Our calculations are based on comprehensive, delayed quotes.

Stock Money Flow

  • Uptick/Downtick Trade Ratio
    0 2
    0.90
    Net Money Flow ()
    -1.36 M

    Money flow gives a snapshot of relative buying and selling pressure in a stock. A ratio above one suggests greater buying pressure, below one suggests greater selling.

Advertisement

Competitors CLRB

Company Change P/E (TTM)
XNPT

XenoPort Inc.

 +56.59% -
AMAG

AMAG Pharmaceuticals Inc.

 +0.69% 106.00
TLOG

TetraLogic Pharmaceuticals Corp.

 +3.75% -
CNCE

Concert Pharmaceuticals Inc.

 +1.02% 15.85

Profile CLRB

Cellectar BioSciences, Inc. operates as a biopharmaceutical company that is engaged in developing compounds for the treatment and imaging of cancer. Its cancer-targeting technology permits selective delivery of a wide range of agents to cancer cells, including cancer...

3301 Agriculture Drive
Madison Wisconsin 53716
United States

  • Employees 19
    Sector Pharmaceuticals
  • Sales or Revenue -
    Industry Health Care/Life Sciences
  • 1Y Sales Change -
    Fiscal Year Ends December 31 Download Reports

Research & Ratings Cellectar Biosciences Inc.CLRB

Per-Share Earnings, Actuals and Estimates

CLRB will report Q2 earnings on 08/17/2016
Actual Analyst Range Consensus
N/A
N/A
N/A
N/A
N/A
N/A
Q3 2016 Estimate Trends
Current: $-
1 month ago: $-
3 months ago: $-

Financials Cellectar Biosciences Inc.CLRB

Net Income

0 9M
0 -9M
Mar 2015 Jun 2015 Sep 2015 Dec 2015 Mar 2016
Mar 2016 5-quarter trend
Net Income Growth -
Sales or Revenue -
Sales or Revenue Growth -
EBITDA -
2015 5-year trend
Net Income Growth +32.21%
Sales or Revenue -
Sales or Revenue Growth -
EBITDA -8.19 M

Notes & Data Providers

Real-time U.S. stock quotes reflect trades reported through Nasdaq only.

International stock quotes are delayed as per exchange requirements. Indexes may be real-time or delayed; refer to time stamps on index quote pages for information on delay times.

Quote data, except U.S. stocks, provided by SIX Financial Information.

Data is provided "as is" for informational purposes only and is not intended for trading purposes. SIX Financial Information (a) does not make any express or implied warranties of any kind regarding the data, including, without limitation, any warranty of merchantability or fitness for a particular purpose or use; and (b) shall not be liable for any errors, incompleteness, interruption or delay, action taken in reliance on any data, or for any damages resulting therefrom. Data may be intentionally delayed pursuant to supplier requirements.

All of the mutual fund and ETF information contained in this display was supplied by Lipper, A Thomson Reuters Company, subject to the following: Copyright © Thomson Reuters. All rights reserved. Any copying, republication or redistribution of Lipper content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Lipper. Lipper shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Bond quotes are updated in real-time. Source: Tullett Prebon.

Currency quotes are updated in real-time. Source: Tullet Prebon.

Fundamental company data and analyst estimates provided by FactSet. Copyright FactSet Research Systems Inc. All rights reserved.

Advertisement